Updated on 6 June 2016
Instem, a leading provider of IT solutions to the global early development healthcare market, has announced that BoZo Research Center (BoZo) has chosen them as their exclusive SEND outsourcing partner in Japan. SEND stands for Standard for Exchange of Nonclinical Data.
BoZo says it has been serving the preclinical research community for over 40 years and is one of the leading contract research organizations in Japan with nearly 500 employees located across four sites.
Helping them meet increased market demand, Instem said it will be complementing the existing team at BoZo, providing SEND data conversion and consulting services for organizations throughout Japan. Instem will begin providing services this year and BoZo expects up to 100 preclinical studies will need to be converted into SEND during 2017.
"The market in Japan requires high quality results that are reliable and can be produced cost effectively," stated Koji Takashima, Vice President, Sales and Market Development at BoZo. "Through Instem, we now have access to the world's foremost experts in SEND and our entire client community will be able to Submit with Confidence."
The Food & Drug Administration reports that 11% of new drug approvals in 2015 were from Japanese organizations and that rate is expected to continue and possibly rise in the future. Instem has been serving the Japanese marketplace since 2005 and during 2015 has opened a new office in Tokyo, and has hired additional local staff and increased its technology offerings to help meet market demand.